Literature DB >> 19525463

Qualification of PET scanners for use in multicenter cancer clinical trials: the American College of Radiology Imaging Network experience.

Joshua S Scheuermann1, Janet R Saffer, Joel S Karp, Anthony M Levering, Barry A Siegel.   

Abstract

UNLABELLED: The PET Core Laboratory of the American College of Radiology Imaging Network (ACRIN) qualifies sites to participate in multicenter research trials by quantitatively reviewing submitted PET scans of uniform cylinders to verify the accuracy of scanner standardized uptake value (SUV) calibration and qualitatively reviewing clinical PET images from each site. To date, cylinder and patient data from 169 PET scanners have been reviewed, and 146 have been qualified.
METHODS: Each site is required to submit data from 1 uniform cylinder and 2 patient test cases. Submitted phantom data are analyzed by drawing a circular region of interest that encompasses approximately 90% of the diameter of the interior of the phantom and then recording the mean SUV and SD of each transverse slice. In addition, average SUVs are measured in the liver of submitted patient scans. These data illustrate variations of SUVs across PET scanners and across institutions, and comparison of results with values submitted by the site indicate the level of experience of PET camera operators in calculating SUVs.
RESULTS: Of 101 scanner applications for which detailed records of the qualification process were available, 12 (12%) failed because of incorrect SUV or normalization calibrations. For sites to pass, the average cylinder SUV is required to be 1.0 +/- 0.1. The average SUVs for uniform cylinder images for the most common scanners evaluated-Siemens Biograph PET/CT (n = 43), GE Discovery LS PET/CT (n = 15), GE Discovery ST PET/CT (n = 34), Philips Allegro PET (n = 5), and Philips Gemini PET/CT (n = 11)-were 0.99, 1.01, 1.00, 0.98, and 0.95, respectively, and the average liver SUVs for submitted test cases were 2.34, 2.13, 2.27, 1.73, and 1.92, respectively.
CONCLUSION: Minimizing errors in SUV measurement is critical to achieving accurate quantification in clinical trials. The experience of the ACRIN PET Core Laboratory shows that many sites are unable to maintain accurate SUV calibrations without additional training or supervision. This raises concerns about using SUVs to quantify patient data without verification.

Entities:  

Mesh:

Year:  2009        PMID: 19525463      PMCID: PMC2744888          DOI: 10.2967/jnumed.108.057455

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  8 in total

1.  Standardized uptake values of fluorine-18 fluorodeoxyglucose: the value of different normalization procedures.

Authors:  A Schomburg; H Bender; C Reichel; T Sommer; J Ruhlmann; B Kozak; H J Biersack
Journal:  Eur J Nucl Med       Date:  1996-05

2.  Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials.

Authors:  Lalitha K Shankar; John M Hoffman; Steve Bacharach; Michael M Graham; Joel Karp; Adriaan A Lammertsma; Steven Larson; David A Mankoff; Barry A Siegel; Annick Van den Abbeele; Jeffrey Yap; Daniel Sullivan
Journal:  J Nucl Med       Date:  2006-06       Impact factor: 10.057

Review 3.  ACR accreditation of nuclear medicine and PET imaging departments.

Authors:  Carolyn Richards MacFarlane
Journal:  J Nucl Med Technol       Date:  2006-03

4.  The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials.

Authors:  Ronald Boellaard; Wim J G Oyen; Corneline J Hoekstra; Otto S Hoekstra; Eric P Visser; Antoon T Willemsen; Bertjan Arends; Fred J Verzijlbergen; Josee Zijlstra; Anne M Paans; Emile F I Comans; Jan Pruim
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-08-15       Impact factor: 9.236

5.  FDG-PET standardized uptake values in normal anatomical structures using iterative reconstruction segmented attenuation correction and filtered back-projection.

Authors:  C D Ramos; Y E Erdi; M Gonen; E Riedel; H W Yeung; H A Macapinlac; R Chisin; S M Larson
Journal:  Eur J Nucl Med       Date:  2001-02

6.  Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group.

Authors:  H Young; R Baum; U Cremerius; K Herholz; O Hoekstra; A A Lammertsma; J Pruim; P Price
Journal:  Eur J Cancer       Date:  1999-12       Impact factor: 9.162

7.  Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose: variations with body weight and a method for correction.

Authors:  K R Zasadny; R L Wahl
Journal:  Radiology       Date:  1993-12       Impact factor: 11.105

8.  Within-patient variability of (18)F-FDG: standardized uptake values in normal tissues.

Authors:  Nancy Paquet; Adelin Albert; Jacqueline Foidart; Roland Hustinx
Journal:  J Nucl Med       Date:  2004-05       Impact factor: 10.057

  8 in total
  49 in total

1.  Proposal for the standardisation of multi-centre trials in nuclear medicine imaging: prerequisites for a European 123I-FP-CIT SPECT database.

Authors:  John Caddell Dickson; Livia Tossici-Bolt; Terez Sera; Robin de Nijs; Jan Booij; Maria Claudia Bagnara; Anita Seese; Pierre Malick Koulibaly; Umit Ozgur Akdemir; Cathrine Jonsson; Michel Koole; Maria Raith; Markus Nowak Lonsdale; Jean George; Felicia Zito; Klaus Tatsch
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-01       Impact factor: 9.236

2.  Accuracy of PET-CT in predicting survival in patients with esophageal cancer.

Authors:  Claire Brown; Ben Howes; Glyn G Jamieson; Dylan Bartholomeusz; Urs Zingg; Thomas R Sullivan; Sarah K Thompson
Journal:  World J Surg       Date:  2012-05       Impact factor: 3.352

3.  Variability in PET quantitation within a multicenter consortium.

Authors:  Frederic H Fahey; Paul E Kinahan; Robert K Doot; Mehmet Kocak; Harold Thurston; Tina Young Poussaint
Journal:  Med Phys       Date:  2010-07       Impact factor: 4.071

4.  Instrumentation factors affecting variance and bias of quantifying tracer uptake with PET/CT.

Authors:  R K Doot; J S Scheuermann; P E Christian; J S Karp; P E Kinahan
Journal:  Med Phys       Date:  2010-11       Impact factor: 4.071

5.  A Phase II Study of 3'-Deoxy-3'-18F-Fluorothymidine PET in the Assessment of Early Response of Breast Cancer to Neoadjuvant Chemotherapy: Results from ACRIN 6688.

Authors:  Lale Kostakoglu; Fenghai Duan; Michael O Idowu; Paul R Jolles; Harry D Bear; Mark Muzi; Jean Cormack; John P Muzi; Daniel A Pryma; Jennifer M Specht; Linda Hovanessian-Larsen; John Miliziano; Sharon Mallett; Anthony F Shields; David A Mankoff
Journal:  J Nucl Med       Date:  2015-09-10       Impact factor: 10.057

6.  Pretreatment 18F-FDG PET Textural Features in Locally Advanced Non-Small Cell Lung Cancer: Secondary Analysis of ACRIN 6668/RTOG 0235.

Authors:  Nitin Ohri; Fenghai Duan; Bradley S Snyder; Bo Wei; Mitchell Machtay; Abass Alavi; Barry A Siegel; Douglas W Johnson; Jeffrey D Bradley; Albert DeNittis; Maria Werner-Wasik; Issam El Naqa
Journal:  J Nucl Med       Date:  2016-02-11       Impact factor: 10.057

7.  Performance evaluation of the Ingenuity TF PET/CT scanner with a focus on high count-rate conditions.

Authors:  Jeffrey A Kolthammer; Kuan-Hao Su; Anu Grover; Manoj Narayanan; David W Jordan; Raymond F Muzic
Journal:  Phys Med Biol       Date:  2014-06-23       Impact factor: 3.609

8.  Early response monitoring to neoadjuvant chemotherapy in osteosarcoma using sequential ¹⁸F-FDG PET/CT and MRI.

Authors:  Byung Hyun Byun; Chang-Bae Kong; Ilhan Lim; Byung Il Kim; Chang Woon Choi; Won Seok Song; Wan Hyeong Cho; Dae-Geun Jeon; Jae-Soo Koh; Soo-Yong Lee; Sang Moo Lim
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-03-21       Impact factor: 9.236

9.  Commentary: an eye on PET quantification.

Authors:  Matthew D Walker; Vesna Sossi
Journal:  Mol Imaging Biol       Date:  2015-02       Impact factor: 3.488

10.  Prediction of survival by [18F]fluorodeoxyglucose positron emission tomography in patients with locally advanced non-small-cell lung cancer undergoing definitive chemoradiation therapy: results of the ACRIN 6668/RTOG 0235 trial.

Authors:  Mitchell Machtay; Fenghai Duan; Barry A Siegel; Bradley S Snyder; Jeremy J Gorelick; Janet S Reddin; Reginald Munden; Douglas W Johnson; Larry H Wilf; Albert DeNittis; Nancy Sherwin; Kwan Ho Cho; Seok-Ki Kim; Gregory Videtic; Donald R Neumann; Ritsuko Komaki; Homer Macapinlac; Jeffrey D Bradley; Abass Alavi
Journal:  J Clin Oncol       Date:  2013-09-16       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.